New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AEON Biopharma, Inc. (AEON) vs BioCardia, Inc. (BCDA)

AEON Biopharma, Inc. and BioCardia, Inc. are both Biotechnology companies. AEON Biopharma, Inc. and BioCardia, Inc. are of similar size ($11.7M and $11.2M). Across the 9 metrics below, BioCardia, Inc. leads on 5 and AEON Biopharma, Inc. on 4.

Valuation

Metric AEON BCDA Biotechnology median
P/E n/m n/m 8.49
P/S — 26.88 8.56
P/B 4.90 13.78 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales — 21.68 8.00
Earnings yield (3,078.92%) (84.95%) (35.81%)
Free cash flow yield (143.41%) (66.25%) (25.41%)

Profitability

Metric AEON BCDA Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin — (2,010.75%) 0.00%
Net margin — (1,999.77%) 0.00%
Free cash flow margin — — 0.00%
Return on equity 544.66% (443.27%) (51.58%)
Return on assets (416.57%) (166.46%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AEON BCDA Biotechnology median
Revenue growth (TTM) — 0.71% 7.20%
EPS growth (last fiscal year) (105.42%) 57.59% 29.04%
Revenue growth, 5-year CAGR — 26.89% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AEON BCDA Biotechnology median
Debt to equity 0.83 0.00 0.00
Current ratio 2.75 1.11 4.79
Net debt to EBITDA (2.48) 0.30 1.01

Dividend

Metric AEON BCDA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AEON BCDA Biotechnology median
Market cap 11.20m 11.70m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack